Exelixis, Inc.
Exelixis, Inc. (EXEL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EXEL · as of Mar 31, 2025
Ownership Breakdown
581
Institutional Holders
▲ 39 vs Q4
$9.40B
Total Inst. Value
▲ $1.07B vs Q4
251.36M
Shares Outstanding
freeFloat 81.34%
254.88M
13F Shares Held
▲ 4.36M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EXEL largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 30.36M | 10.89% | 10.89% | $1.12T | May 2, 2025 | ▲ 40.9K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 28.67M | 10.28% | 10.28% | $1.06T | May 9, 2025 | ▼ 757.3K |
FARALLON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 22.53M | 8.08% | 8.08% | $831.94B | May 15, 2025 | ▼ 906.0K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 14.82M | 5.32% | 5.32% | $547.31B | May 14, 2025 | ▼ 471.6K |
STATE STREET CORP biological products, (no diagnostic substances) | 11.79M | 4.23% | 4.23% | $435.27B | May 15, 2025 | ▲ 377.7K |
LSV ASSET MANAGEMENT biological products, (no diagnostic substances) | 8.16M | 2.93% | 2.93% | $301.32B | May 9, 2025 | ▼ 8.5K |
FULLER & THALER ASSET MANAGEMENT, INC. biological products, (no diagnostic substances) | 7.80M | 2.80% | 2.80% | $287.79B | May 13, 2025 | ▲ 164.1K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 7.42M | 2.66% | 2.66% | $273.90B | May 13, 2025 | ▲ 2.26M |
AQR CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 6.89M | 2.47% | 2.47% | $250.87B | May 15, 2025 | ▲ 2.93M |
INVESCO LTD. biological products, (no diagnostic substances) | 5.57M | 2.00% | 2.00% | $205.73B | May 12, 2025 | ▲ 1.60M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
23
Increased
+12.85M shares1
New Positions
first time holders24
Decreased
−10.94M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.91M
+12.85M / −10.94M
Net new holders
+0
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EXEL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
16
Sell transactions
0.81
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
WYSZOMIERSKI JACK L director | Jun 1, 2026 | Sale | 3,925 | $50.55 | $198.4K | 284.4K | Form 4 ↗ |
Eckhardt Sue Gail director | Jun 1, 2026 | Sale | 9,812 | $50.14 | $492.0K | 16.1K | Form 4 ↗ |
PAPADOPOULOS STELIOS director | May 27, 2026 | Award | 8,367 | — | — | 1.20M | Form 4 ↗ |
Heyman Tomas J. director | May 27, 2026 | Award | 8,367 | — | — | 50.6K | Form 4 ↗ |
Eckhardt Sue Gail director | May 27, 2026 | Award | 8,367 | — | — | 25.9K | Form 4 ↗ |
Smith Julie director | May 27, 2026 | Award | 8,367 | — | — | 29.0K | Form 4 ↗ |
Freire Maria C director | May 27, 2026 | Award | 8,367 | — | — | 109.2K | Form 4 ↗ |
Beckerle Mary C director | May 27, 2026 | Award | 8,367 | — | — | 25.9K | Form 4 ↗ |
Oliver Bob director | May 27, 2026 | Award | 8,367 | — | — | 29.5K | Form 4 ↗ |
WYSZOMIERSKI JACK L director | May 27, 2026 | Award | 8,367 | — | — | 288.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Exelixis, Inc. (EXEL) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 18.66%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Exelixis, Inc. is BLACKROCK, INC., holding approximately 30.36 million shares — equal to 10.89% of outstanding shares — as of March 31, 2025.
A total of 581 institutional investors currently hold EXEL stock, with a combined institutional value of approximately $9.40 billion as of the most recent 13F filing period.
Frequently asked questions
EXEL ownershipExelixis, Inc. (EXEL) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 10.89% stake. Company insiders hold 18.66%. Data sourced from SEC Form 13F as of March 31, 2025.